NCT02850406

Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease

Emerging clinical data evaluated by Pfizer and shared with regulatory authorities indicates that the risk profile of voxelotor in people with SCD exceeds the benefits observed in previously generated global research and requires further assessment.